natgillin/translations-raw huggingface dataset:
Lonquex may be removed from the refrigerator and stored below 25 °C for a maximum single period of up to 3 days.
Lonquex se može izvaditi iz hladnjaka i čuvati na temperaturi ispod 25 °C tijekom jednog razdoblja do najviše 3 dana.
Lonquex should not be used to increase the dose of cytotoxic chemotherapy beyond established dosage regimens.
Lonquex se ne smije primjenjivati kako bi se doza citotoksičnih kemoterapeutika povisila iznad ustanovljenih režima doziranja.
Lonquex treatment should be initiated and supervised by physicians experienced in oncology or haematology.
Liječenje Lonquexom trebaju započeti i nadzirati liječnici s iskustvom u onkologiji ili hematologiji.
Lonsurf 15 mg /6.14 mg film-coated tablets trifluridine/tipiracil
Lonsurf 15 mg/6,14 mg filmom obložene tablete trifluridin/tipiracil
Lonsurf 15 mg is a white, biconvex, round, film-coated tablet, printed with “15” on one side and “102” and “15 mg” on the other side in grey ink.
Lonsurf 15 mg je bijela, bikonveksna, okrugla filmom obložena tableta, s oznakom “15” na jednoj strani, i “102” i “15 mg” na drugoj, u sivoj tinti.
Lonsurf 15 mg tablet
Lonsurf 15 mg tablete
Lonsurf 15 mg/6.14 mg film-coated tablets
Lonsurf 15 mg/ 6,14 mg filmom obložene tablete
Lonsurf 15 mg/6.14 mg film-coated tablets Lonsurf 20 mg/8.19 mg film-coated tablets
Lonsurf 15 mg/6,14 mg filmom obložene tablete Lonsurf 20 mg/8,19 mg filmom obložene tablete
Lonsurf 15 mg/6.14 mg tablets trifluridine/tipiracil
Lonsurf 15 mg/6,14 mg tablete trifluridin/tipiracil
Lonsurf 20 mg is a pale red, biconvex, round, film-coated tablet, printed with “20” on one side and “102” and “20 mg” on the other side in grey ink.
Lonsurf 20 mg je blijedo crvena, bikonveksna, okrugla filmom obložena tableta, s oznakom “20” na jednoj strani, i “102” i “20 mg” na drugoj, u sivoj tinti.
Lonsurf 20 mg tablet
Lonsurf 20 mg tablete
Lonsurf 20 mg/8.19 mg film-coated tablets
Lonsurf 20 mg/ 8,19 mg mg filmom obložene tablete
Lonsurf 20 mg/8.19 mg film-coated tablets trifluridine/tipiracil
Lonsurf 20 mg/8,10 mg filmom obložene tablete trifluridin/tipiracil
Lonsurf 20 mg/8.19 mg tablets trifluridine/tipiracil
Lonsurf 20 mg/8,19 mg tablete trifluridin/tipiracil
Lonsurf caused an increase in the incidence of myelosuppression including anaemia, neutropenia, leucopenia, and thrombocytopenia.
Lonsurf je uzrokovao povećanu incidenciju mijelosupresije uključujući anemiju, neutropeniju, leukopeniju i trombocitopeniju.
Lonsurf dosing was based on BSA with a starting dose of 35 mg/m2/dose.
Doziranje Lonsurfa se temeljilo na PT s početnom dozom 35 mg/m2/dozi.
Lonsurf had no clinically relevant effect on QT/QTc prolongation compared with placebo in an open label study in patients with advanced solid tumours.
U otvorenom ispitivanju u bolesnika s uznapredovalim solidnim tumorima Lonsurf nije imao klinički relevantan učinak na produljenje QT/QTc intervala u usporedbi s placebom.
Lonsurf has been shown to prolong overall survival of patients with metastatic colorectal cancer who previously received other treatments.
Pokazalo se da lijek Lonsurf produljuje ukupni vijek preživljavanja bolesnika s metastatskim rakom debelog crijeva koji su prethodno primali druge terapije.
Lonsurf is a cancer medicine used to treat adults with metastatic colorectal cancer (cancer of the large bowel that has spread to other parts of the body).
Lonsurf je lijek za liječenje raka koji se primjenjuje za liječenje odraslih osoba s metastatskim kolorektalnim rakom (rakom debelog crijeva koji se proširio na druge dijelove tijela).
Lonsurf is a cytotoxic medicine (a medicine that kills cells that are dividing, such as cancer cells).
Lonsurf je citotoksičan lijek (lijek koji ubija stanice koje se dijele, kao što su stanice raka).
Lonsurf is available as tablets (15 mg trifluridine and 6.14 mg tipiracil; 20 mg trifluridine and 8.19 mg tipiracil) and is given in treatment cycles of 28 days.
Lonsurf je dostupan u obliku tableta (15 mg trifluridina i 6,14 mg tipiracila; 20 mg trifluridina i 8,19 mg tipiracila) i daje se u ciklusima liječenja od 28 dana.
Lonsurf is comprised of an antineoplastic thymidine-based nucleoside analogue, trifluridine, and the thymidine phosphorylase (TPase) inhibitor, tipiracil hydrochloride, at a molar ratio 1:0.5 (weight ratio, 1:0.471).
Lonsurf je sastavljen od trifluridina, nukleozidnog analoga koji se zasniva na timidinu a ima antineoplastični učinak, i tipiracilklorida, inhibitora timidin fosforilaze (TPaze), u molarnom omjeru 1:0,5 (maseni omjer 1:0,471).
Lonsurf is indicated for the treatment of adult patients with metastatic colorectal cancer (CRC) who have been previously treated with, or are not considered candidates for, available therapies including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-VEGF agents, and anti-EGFR agents.
Lonsurf je indiciran za liječenje odraslih bolesnika s metastatskim kolorektalnim karcinomom (KRK) koji su prethodno liječeni, ili se ne smatraju kandidatima za liječenje dostupnim terapijama, uključujući kemoterapije koje se zasnivaju na fluoropirimidinu, oksaliplatinu i irinotekanu, anti-VEGF lijekove i anti-EGFR lijekove
Lonsurf is not recommended for use in patients with moderate or severe hepatic impairment (National Cancer Institute [NCI] Criteria Group C and D) as Lonsurf has not been studied in these patients (see section 5.2).
Primjena Lonsurfa se ne preporučuje u bolesnika s umjerenim ili teškim oštećenjem jetre (prema NCI [National Cancer Institute] klasifikaciji skupina C i D) jer Lonsurf nije ispitivan kod tih bolesnika (vidjeti dio 5.2).
Lonsurf is used to treat adults with colon or rectal cancer - sometimes called ‘colorectal’ cancer.
Lonsurf se primjenjuje u odraslih bolesnika za liječenje raka debelog ili završnog dijela debelog crijeva - koji se ponekad naziva kolorektalni karcinom.
Lonsurf plus BSC (N=534)
Lonsurf uz BSC (N=534)
Lonsurf trifluridine/tipiracil
Lonsurf trifluridin/tipiracil
Lonza Biologics Inc., 101 International Drive, Portsmouth, NH 03801-2815, USA Name and address of the manufacturers responsible for batch release
Lonza Biologics Inc., 101 International Drive, Portsmouth, NH 03801-2815, SAD Naziv i adresa proizvođača odgovornih za puštanje serije lijeka u promet
Look at the cartridge before you use it.
Pregledajte uložak prije nego što ga upotrijebite.
Look at the cartridge sealed in the disposable pen injector before you use it.
Pregledajte uložak ugrađen u jednokratnu brizgalicu prije nego što je upotrijebite.
Look at the expiry date on the box to be used.
Provjerite rok valjanosti na kutiji koju ćete koristiti.
Look at the expiry date on the pack and dose tray.
Provjerite rok valjanosti na pakiranju i doznom spremniku.
Look at the expiry date on the pre-filled pen and pack.
Provjerite rok valjanosti na napunjenoj brizgalici i pakiranju.
Look at the expiry date on the syringe and pack.
Provjerite rok valjanosti na štrcaljki i pakiranju.
Look at the expiry date on the syringe.
Provjerite rok valjanosti na štrcaljki.
Look at the final solution to check for particulate matter or discolouration.
Pregledajte dobivenu otopinu da ne sadrži čestice i nije promijenila boju.
Look at the inhaler to make sure it is not damaged or dirty.
Pregledajte inhalator kako biste bili sigurni da nije oštećen ili prljav.
Look at the liquid in the syringe window (Figure 2).
Pogledajte tekućinu u štrcaljki (Slika 2).
Look at the liquid through the viewing window of the pre-filled syringe and make sure that it is clear to slightly opalescent (having a pearl-like shine) and colourless to light yellow.
Pogledajte kroz prozorčić napunjene štrcaljke kako bi se uvjerili da je tekućina u napunjenoj štrcaljki bistra do blago opalescentna (ima biserni odsjaj) te bezbojna do žućkasta.
Look at the medicine in the pre-filled syringe.
Pogledajte lijek u napunjenoj štrcaljki.
Look at the medicine through the viewing window.
Pogledajte lijek kroz kontrolni prozorčić.
Look at the right column to check the number of capsules you will need to give the patient for a single dose.
Pogledajte stupac na desnoj strani tablice da provjerite koliko kapsula Vam je potrebno da biste bolesniku dali jednu dozu.
Look at the vial before you use it.
Pregledajte bočicu prije nego što je upotrijebite.
Look carefully at the reservoir holder.
Pozorno nadzirite držač spremnika.
Look carefully at the solution you prepared before you use it.
Pažljivo promotrite izgled pripremljene otopine prije nego je primijenite.
LOOK FOR PARTICLES
PROVJERITE IMA LI ČESTICA
Look for the line that shows how much the adult or child/adolescent weighs.
Pronađite redak koji pokazuje tjelesnu težinu odrasle osobe ili djeteta/adolescenta.
Look for the needle tip inside the stopper window (see Diagram 4).
Provjerite vidi li se vrh igle u prozorčiću čepa (vidjeti sliku 4).
Look in the window.
Pogledajte kroz prozorčić.
Look into your child’s mouth to make sure that all the medicine has been swallowed.
Provjerite da u ustima Vašeg djeteta nije ostalo neprogutanog lijeka.
Look out for any symptoms of infection or other symptoms such as:
Pazite na bilo koje simptome infekcije ili druge simptome poput:
Look out for any symptoms of infection or other symptoms such as:
Pripazite na bilo kakve simptome infekcije ili druge simptome poput:
Look out for infections.
Obratite pozornost na infekcije.
look out for possible signs of lactic acidosis – see section 4, Possible side effects.
pazite na moguće znakove laktacidoze – vidjeti dio 4 Moguće nuspojave.
Look out for serious symptoms
Obratite pozornost na ozbiljne simptome
Look out for the following:
Pazite na sljedeće:
Look through the oval display window.
Pogledajte kroz ovalni prozorčić za prikaz lijeka.
Look through the transparent window to make sure that the plunger has moved to the bottom as indicated in the figure.
Pogledajte kroz prozirni prozorčić kako biste se uvjerili da se klip pomaknuo prema dnu kako je to naznačeno na slici.
Look through the viewing window to check that the liquid in the cartridge is clear and free of solid particles.
Pogledajte kroz prozorčić kako biste provjerili je li tekućina u ulošku bistra i bez čestica.
Look through the viewing window to make sure that the liquid in the pre-filled pen is clear to slightly opalescent (having a pearl-like shine) and colourless to light yellow.
Pogledajte kroz prozorčić brizgalice kako bi se uvjerili da je tekućina u napunjenoj brizgalici bistra do blago opalescentna (ima biserni odsjaj) te bezbojna do žućkasta.
Look to see if the capsule is empty - the capsule must spin in the inhaler in order to empty.
Provjerite je li kapsula prazna – kapsula se mora vrtjeti u inhalatoru kako bi se ispraznila.
Look to see that nothing is blocking the mouthpiece.
Provjerite da ništa ne blokira nastavak za usta.
Look up the child’s weight on the left side of the table.
Potražite djetetovu tjelesnu težinu na lijevoj strani tablice.
Looking at the results of both studies together, 55% of the patients (298 out of 541) taking Emend capsules at a dose of 40 mg had a complete response, compared with 49% of the patients who received ondansetron (258 out of 526).
Promatrajući rezultate obaju ispitivanja zajedno, u 55% bolesnika (298 od 541) koji su uzimali kapsule lijeka Emend u dozi od 40 mg zabilježena je potpuna reakcija, u usporedbi s 49% bolesnika koji su primali ondansetron (258 od 526).
Looking at the results of the two studies taken together, 55% of the patients receiving Relistor opened their bowels within four hours after the first injection (91 out of 165), compared with 15% of the patients receiving placebo (18 out of 123).
Promatrajući rezultate oba ispitivanja zajedno, kod 55 % bolesnika koji su primili Relistor došlo je do otvaranja crijeva unutar četiri sata nakon prve injekcije (91 od 165), u usporedbi s 15 % bolesnika koji su primali placebo (18 od 123).
Looking at the results of these follow-up studies together, 2 years after starting treatment 75% of patients who received Deltyba for 6 months or more had no bacteria in their sputum compared with 55% of patients who received Deltyba for 2 months or less.
Gledajući rezultate ovih praćenih ispitivanja, 2 godine nakon početka liječenja, 75 % bolesnika koji su primali lijek Deltyba tijekom 6 mjeseci ili duže nisu imali bakteriju u sputumu u usporedbi s 55 % bolesnika koji su primali lijek Deltyba tijekom 2 mjeseca ili kraće.
Looking at the two studies in adults together, the average viral load was 70,000 copies/ml at the start of the studies.
Promatrajući dva ispitivanja provedena u odraslih bolesnika zajedno, prosječno virusno opterećenje iznosilo je 70.000 kopija/ml na početku ispitivanja.
looking flushed increased blood pressure
crvenilo povišeni krvni tlak
looking pale, feeling low in energy or tired
blijed izgled, osjećaj niske energije ili umora
Loose debris should be gently removed from the external ear canal at each treatment.
Prije liječenja savjetuje se cerumenolitikom pažljivo očistiti zvukovod.
Loose debris should be gently removed from the external ear canal at the time of treatment.
Prije liječenja savjetuje se cerumenolitikom pažljivo očistiti zvukovod.
Loose nails
paronihija
loose or watery stools
mekane ili vodenaste stolice
loose stools (diarrhoea)
mekana stolica (proljev)
loose stools (diarrhoea)
mekane stolice (proljev)
loose stools (diarrhoea) feeling tired (fatigue)
mekana stolica (proljev) osjećaj umora (umor)
Loose stools, nausea, vomiting, abdominal pain
Meka stolica, mučnina, povraćanje, bol u abdomenu
Loperamide 16 mg QD
Loperamid 16 mg QD
Loperamide AUC ↓ 51%
Flutikazonpropionat
Loperamide Cmax ↓ 61%
Loperamid Cmax ↓ 61% Loperamid AUC ↓ 51
Loperamide Cmax ↓ 61% Loperamide AUC ↓ 51%
Loperamid Cmax ↓ 61% Loperamid AUC ↓ 51
Loperamide was administered to 13 % of patients in 5 % of courses.
Loperamid je primijenjen u 13% bolesnika, u 5% ciklusa.
Lopinavir / ritonavir
lopinavir /
Lopinavir 400 mg / Ritonavir 100 mg (CYP3A4/5 strong inhibitors and substrates)
Lopinavir 400 mg / ritonavir 100 mg (snaţni inhibitori i supstrati za CYP3A4/5)
lopinavir 400 mg and ritonavir 100 mg twice daily
lopinavir 400 mg i ritonavir 100 mg dvaput na dan
Lopinavir and ritonavir levels may increase on stopping St John’s wort.
Pri obustavi gospine trave mogu se povisiti razine lopinavira i ritonavira.
Lopinavir AUC over a 24 hour dosing interval averaged 206.5 ± 89.7 μg h/ml.
Vrijednost AUC lopinavira je tijekom 24 satnog doziranja prosiječno bila 206,5 ± 89,7 μg·h/ml.
Lopinavir AUC over a 24 hour dosing interval averaged 206.5 ± 89.7 gh/ml.
Vrijednost AUC lopinavira je tijekom 24 satnog doziranja prosječno bila 206,5 ± 89,7 μg·h/ml.
Lopinavir AUC ↓ 0.73 (0.53-0.98)
Lopinavir AUC  0,73 (0,53-0,98)
Lopinavir AUC ↓ 0.78 (0.56-1.09)
Lopinavir AUC  0,78 (0,56-1,09)
Lopinavir AUC  0.73 (0.53-0.98)
Lopinavir AUC  0,73 (0,53-0,98)
Lopinavir AUC  0.78 (0.56-1.09)
Lopinavir AUC  0,78 (0,56-1,09)
Lopinavir binds to both alpha- 1-acid glycoprotein (AAG) and albumin, however, it has a higher affinity for AAG.
Lopinavir se veže i na alfa-1-kiseli glikoprotein (AAG) i na albumin, no ima veći afinitet za AAG.
Lopinavir can be used during pregnancy if clinically needed.
Pri obustavi gospine trave mogu se povisiti razine lopinavira i ritonavira.
Lopinavir Cmax ↓ 0.81 (0.62-0.95)
Lopinavir Cmax  0,81 (0,62-0,95)
Lopinavir Cmax ↓ 0.86 (0.64-1.16)
Lopinavir Cmax  0,86 (0,64-1,16)
Lopinavir Cmax  0.81 (0.62-0.95)
Lopinavir Cmax  0,81 (0,62-0,95)
Lopinavir Cmax  0.86 (0.64-1.16)
Lopinavir Cmax  0,86 (0,64-1,16)
lopinavir Cmin ↑ 13%
lopinavir Cmin ↑ 13% lopinavir Cmax ↑ 11
Lopinavir Cmin ↓ 0.45 (0.25-0.82)
Lopinavir Cmin  0,45 (0,25-0,82)
Lopinavir Cmin ↓ 0.54 (0.28-0.74)
Lopinavir Cmin  0,54 (0,28-0,74)
Lopinavir Cmin  0.45 (0.25-0.82)
Lopinavir Cmin  0,45 (0,25-0,82)
Lopinavir Cmin  0.54 (0.28-0.74)
Lopinavir Cmin  0,54 (0,28-0,74)
Lopinavir co-formulated with ritonavir (lopinavir/ritonavir) 400 mg/100 mg or 800 mg/200mg.
Lopinavir u formulaciji s ritonavirom (lopinavir/ritonavir) 400 mg/100 mg ili 800 mg/200 mg.
Lopinavir concentrations: ↓ 30-40%
Koncentracije lopinavira: ↓ 30-40
Lopinavir provides the antiviral activity of Kaletra.
Za antivirusnu aktivnost lijeka Kaletra odgovoran je lopinavir.
Lopinavir provides the antiviral activity of lopinavir/ritonavir.
Za antivirusnu aktivnost lopinavira/ritonavira odgovoran je lopinavir.
Lopinavir  (based on historical comparison with unboosted lopinavir)
Lopinavir  (na temelju povijesne usporedbe s nepojačanim lopinavirom)
Lopinavir  Ritonavir 
C24 6% lopinavir  ritonavir 
Lopinavir  Ritonavir  Etravirine 
lopinavir  ritonavir  etravirin 
Lopinavir+ritonavir (and other ritonavir-boosted protease inhibitors): co-administration of bosentan 125 mg twice daily and lopinavir+ritonavir 400+100 mg twice daily for 9.5 days in healthy volunteers resulted in initial trough plasma concentrations of bosentan that were approximately 48-fold higher than those measured after bosentan administered alone.
Lopinavir + ritonavir (i drugi ritonavirom pojačani inhibitori proteaze): istodobna primjena bosentana 125 mg dvaput dnevno i lopinavira 400 mg + ritonavira 100 mg dvaput dnevno kroz 9,5 dana kod zdravih dobrovoljaca rezultirala je početnim najnižim koncentracijama bosentana u plazmi koje su bile približno 48 puta više od onih izmjerenih nakon primjene bosentana samostalno.
Lopinavir+ritonavir (and other ritonavir-boosted protease inhibitors): co-administration of bosentan 125 mg twice daily and lopinavir+ritonavir 400+100 mg twice daily for 9.5 days in healthy volunteers resulted in initial trough plasma concentrations of bosentan that were approximately 48-fold higher than those measured after bosentan administered alone.
Lopinavir+ritonavir (i drugi ritonavirom pojačani inhibitori proteaze): istodobna primjena bosentana 125 mg dvaput dnevno i lopinavira 400 mg + ritonavira 100 mg dvaput dnevno kroz 9,5 dana kod zdravih dobrovoljaca rezultirala je početnim najnižim koncentracijama bosentana u plazmi koje su bile približno 48 puta više od onih izmjerenih nakon primjene bosentana samostalno.
Lopinavir+ritonavir+etravirine/ Dolutegravir
lopinavir+ritonavir+etravirin/ dolutegravir
Lopinavir+ritonavir/ Dolutegravir
lopinavir+ritonavir/dolutegravir
Lopinavir/ritonavir
dolutegravir
Lopinavir/ritonavir
Dolutegravir +
Lopinavir/ritonavir
Sakvinavir/ritonavir
Lopinavir/ritonavir (N=100)
Lopinavir/ritonavir (N = 100)
Lopinavir/ritonavir (N=326)
Lopinavir/ritonavir (N = 326)
Lopinavir/ritonavir (oral solution) 300/75 mg/m2 BID
(oralna otopina) 300/75 mg/m2 2x/dan
Lopinavir/ritonavir + etravirine
lopinavir/ritonavir + etravirin
Lopinavir/ritonavir 400/100 mg twice daily + OBR
400/100 mg dva puta na dan
Lopinavir/ritonavir 800/200 mg was administered in combination with emtricitabine 200 mg and tenofovir DF 300 mg as part of a once daily regimen.
Lopinavir/ritonavir 800/200 mg je davana u kombinaciji s 200 mg emtricitabina i 300 mg tenofovira DF kao dio liječenja jednom dnevno.
lopinavir/ritonavir can be
lopinavir/ritonavir mogu se
Lopinavir/ritonavir does not reduce the risk of passing HIV to others.
Lopinavir/ritonavir ne smanjuje rizik prenošenja HIV-a na druge osobe.
Lopinavir/Ritonavir has been
Pokazalo se da
Lopinavir/ritonavir has not specifically been tested for its possible effects on the ability to drive a car or operate machines.
Nije posebno proučavan učinak lopinavira/ritonavira na na sposobnost upravljanja vozilima i strojevima.
lopinavir/ritonavir is considered necessary, very frequent ECG monitoring throughout the full delamanid treatment period is recommended (see section 4.4 and refer to the delamanid SmPC).
Zbog rizika od produljenja QTc intervala povezanog s DM-6705, ukoliko se istodobna primjena delamanida i ritonavira smatra nužnom, preporučuje se učestalo praćenje EKG-a bolesnika tijekom cijelog razdoblja liječenja delamanidom (vidjeti dio 4.4 i Sažetak opisa svojstava lijeka za delamanid).
Lopinavir/ritonavir is not a cure for HIV infection or AIDS.
Lopinavir/ritonavir neće izliječiti HIV infekciju ili AIDS.
Lopinavir/ritonavir is prescribed for use in combination with other antiviral medicines.
Lopinavir/ritonavir se koristi u kombinaciji s drugim antivirusnim lijekovima.
Lopinavir/ritonavir is used by children 2 years of age or older, adolescents and adults who are infected with HIV, the virus which causes AIDS.
Lopinavir/ritonavir je namijenjen za liječenje djece s navršene 2 godine ili starije, adolescenata i odraslih koji su zaraženi HIV-om, tj. virusom koji uzrokuje sindrom stečene imunodeficijencije (AIDS; engl. acquired immunodeficiency syndrome).
lopinavir/ritonavir must be done with
bi se utvrdilo je li potrebna
Lopinavir/ritonavir must not be administered once daily in combination with amprenavir.
U kombinaciji s amprenavirom lopinavira/ritonavira se ne smije davati jednom dnevno.
Lopinavir/ritonavir must not be administered once daily in combination with efavirenz.
U kombinaciji s efavirenzom lopinavir/ritonavir se ne smije davati jednom dnevno.
Lopinavir/ritonavir must not be administered once daily in combination with nevirapine.
U kombinaciji s nevirapinom lopinavir/ritonavir se ne smije davati jednom dnevno.
Lopinavir/ritonavir must not be taken once daily with efavirenz, nevirapine, carbamazepine, phenobarbital and phenytoin.
Lopinavir/ritonavir se ne smije uzimati jednom dnevno s efavirenzom, nevirapinom, karbamazepinom, fenobarbitalom i fenitoinom.
Lopinavir/Ritonavir Mylan 100 mg/25 mg film-coated tablets
Lopinavir/Ritonavir Mylan 100 mg/25 mg filmom obložene tablete
Lopinavir/Ritonavir Mylan 100 mg/25 mg film-coated tablets are white, film coated, ovaloid, biconvex beveled edge tablets debossed with 'MLR4' on one side of the tablet and plain on the other side.
Lopinavir/Ritonavir Mylan 100 mg/25 mg filmom obložene tablete bijele su, filmom obložene, ovalne, bikonveksne tablete s ukošenim rubom i utisnutom oznakom “MLR4” na jednoj strani tablete i bez ikakve oznake na drugoj strani.
Lopinavir/Ritonavir Mylan 100 mg/25 mg film-coated tablets lopinavir/ritonavir
Lopinavir/Ritonavir Mylan 100 mg/25 mg filmom obložene tablete lopinavir/ritonavir
Lopinavir/Ritonavir Mylan 200 mg/50 mg film-coated tablets
Lopinavir/Ritonavir Mylan 200 mg/50 mg filmom obložene tablete
Lopinavir/Ritonavir Mylan 200 mg/50 mg film-coated tablets are white, film coated, ovaloid, biconvex beveled edge tablets debossed with 'MLR3' on one side of the tablet and plain on the other side.
Lopinavir/Ritonavir Mylan 200 mg/50 mg filmom obložene tablete bijele su, filmom obložene, ovalne, bikonveksne tablete s ukošenim rubom i utisnutom oznakom “MLR3” na jednoj strani tablete i bez ikakve oznake na drugoj strani.
Lopinavir/Ritonavir Mylan 200 mg/50 mg film-coated tablets lopinavir/ritonavir
Lopinavir/Ritonavir Mylan 200 mg/50 mg filmom obložene tablete lopinavir/ritonavir
Lopinavir/Ritonavir Mylan contains the active substances lopinavir and ritonavir.
Lopinavir/Ritonavir Mylan sadrži djelatne tvar lopinavir i ritonavir.
Lopinavir/Ritonavir Mylan contains the active substances lopinavir and ritonavir.
Lopinavir/ritonavir sadrži djelatne tvari lopinavir i ritonavir.
Lopinavir/Ritonavir Mylan is a ‘generic medicine’.
Lopinavir/Ritonavir Mylan je „generički lijek”.
Lopinavir/Ritonavir Mylan lopinavir / ritonavir
Lopinavir/Ritonavir Mylan lopinavir/ritonavir
Lopinavir/Ritonavir Mylan tablets contain lopinavir and ritonavir, both of which are inhibitors of the P450 isoform CYP3A.
Lopinavir/Ritonavir Mylan tablete sadrže lopinavir i ritonavir, koji su oba inhibitori P450 izoforme CYP3A.
Lopinavir/ritonavir plasma
Mogu se smanjiti plazmatske
Lopinavir/ritonavir should always be taken every day to help control your HIV infection, no matter how much better you feel.
Bez obzira koliko se bolje počnete osjećati, lopinavir/ritonavir morate uzimati svaki dan kako bi pomogao u kontroli Vaše HIV infekcije.
Lopinavir/ritonavir should always be taken every day to help control your HIV infection, no matter how much better you feel.
Bez obzira koliko se bolje počnete osjećati, lopinavir/ritonavir morate uzimati svaki dan kako bi pomogla u kontroli Vaše HIV infekcije.
lopinavir/ritonavir should be
lopinavira/ritonavira se mora
Lopinavir/ritonavir soft capsules or oral solution/Efavirenz
lopinavir/ritonavir meke kapsule ili oralna